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o r i g i n a l a r t i c l e
Pseudomonas aeruginosa Nosocomial Pneumonia: Impact of
Pneumonia Classiﬁcation
Scott T. Micek, PharmD;1 Marin H. Kollef, MD;2 Antoni Torres, MD;3 Catherine Chen, MD;2 Jordi Rello, MD;4
Jean Chastre, MD;5 Massimo Antonelli, MD;6 Tobias Welte, MD, PhD;7 Bernard Clair, MD;8 Helmut Ostermann, MD,
PhD;9 Esther Calbo, MD;10 Richard Wunderink, MD;11 Francesco Menichetti, MD, PhD;12 Garrett Schramm, PharmD;13
Vandana Menon, MD14
objective. To describe and compare the mortality associated with nosocomial pneumonia due to Pseudomonas aeruginosa (Pa-NP)
according to pneumonia classiﬁcation (community-onset pneumonia [COP], hospital-acquired pneumonia [(HAP], and ventilator-associated
pneumonia [VAP]).
design. We conducted a retrospective cohort study of adults with Pa-NP. We compared mortality for Pa-NP among patients with COP,
HAP, and VAP and used logistic regression to identify risk factors for hospital mortality and inappropriate initial antibiotic therapy (IIAT).
setting. Twelve acute care hospitals in 5 countries (United States, 3; France, 2; Germany, 2; Italy, 2; and Spain, 3).
patients/participants. A total of 742 patients with Pa-NP.
results. Hospital mortality was greater for those with VAP (41.9%) and HAP (40.1%) compared with COP (24.5%) (P< .001). In
multivariate analyses, independent predictors of hospital mortality differed by pneumonia classiﬁcation (COP: need for mechanical ventilation
and intensive care; HAP: multidrug-resistant isolate; VAP: IIAT, increasing age, increasing Charlson comorbidity score, bacteremia, and use of
vasopressors). Presence of multidrug resistance was identiﬁed as an independent predictor of IIAT for patients with COP and HAP, whereas
recent antibiotic administration was protective in patients with VAP.
conclusions. Among patients with Pa-NP, pneumonia classiﬁcation identiﬁed patients with different risks for hospital mortality. Speciﬁc
risk factors for hospital mortality also differed by pneumonia classiﬁcation and multidrug resistance appeared to be an important risk factor for
IIAT. These ﬁndings suggest that pneumonia classiﬁcation for P. aeruginosa identiﬁes patients with different mortality risks and speciﬁc risk
factors for outcome and IIAT.
Infect. Control Hosp. Epidemiol. 2015;36(10) :1190–1197
Nosocomial pneumonia (NP) can occur in a diverse spectrum
of patients and can be attributed to varied etiologic pathogens.1
NP is typically classiﬁed according to the location and condi-
tions of infection onset (community-onset usually with
healthcare-associated risk factors [COP], hospital-acquired
pneumonia [HAP], or pneumonia acquired during mechan-
ical ventilation).2 Few studies have attempted to evaluate NP
according to the location and conditions of infection or to
compare outcomes among these categories of NP.3–5 Notably,
recent trends show an increase in the prevalence of NP caused
by multidrug-resistant (MDR) gram-negative bacteria, most
commonly Pseudomonas aeruginosa.6–10 Mortality associated
with P. aeruginosa NP (Pa-NP) is among the highest of any
bacteria owing to both the virulence of P. aeruginosa as well as
the administration of inappropriate initial antibiotic therapy
(IIAT) in MDR isolates.11–15
The escalating prevalence of antibiotic resistance in
P. aeruginosa, along with the development and availability of
novel antimicrobial therapies, requires a precise under-
standing of how the various categories of Pa-NP inﬂuence
outcome. A comparison of mortality of Pa-NP, as well as risk
factors for mortality, according to pneumonia classiﬁcation
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has not previously been performed. Pneumonia classiﬁcation
of P. aeruginosa may have important clinical implications,
especially from treatment and infection control perspectives
where typically ventilator-associated pneumonia (VAP) is
primarily evaluated. Therefore, we set out to perform an ana-
lysis of a multinational study of Pa-NP with the following
objectives: ﬁrst, to describe and compare the mortality asso-
ciated with Pa-NP according to pneumonia classiﬁcation;
second, to identify and compare risk factors for hospital
mortality and IIAT according to pneumonia classiﬁcation.
methods
Study Design and Ethical Standards
We conducted a retrospective cohort study in 12 hospitals in
5 countries (United States, 3; France, 2; Germany, 2; Italy, 2;
and Spain, 3). Eligible consecutive patients were aged 18 years
or older and admitted for their index hospitalization within
36 months prior to study initiation in 2013. All eligible patients
met a clinical diagnosis of NP deﬁned as new or progressive
inﬁltrates consistent with pneumonia on chest radiograph or
computed tomography and either a temperature higher than
38.3°C or leukocytosis greater than 10,000 cells/mm3 or both.
To be eligible patients had to have P. aeruginosa cultured from
blood or a respiratory specimen collected from the following:
sputum, pleural ﬂuid, ﬂexible bronchoscopy with protected
specimen brush, bronchoalveolar, or transbronchial biopsy,
“mini-bronchoalveolar” sample, and tracheobronchial aspi-
rate in intubated patients. Microbiologic cultures had to be
obtained within the 24-hour period surrounding initiation of
antibiotics. Pa-NP was classiﬁed as COP, HAP, and VAP
according to the location and conditions of the onset of
infection (COP: prior to hospital admission; HAP: developing
during the hospital stay; VAP: developing while receiving
mechanical ventilation). Patients with COP had to have 1 or
more of the following characteristics to be included: hospita-
lized in an acute care hospital for 2 or more days within 90 days
of infection; resided in a nursing home or long-term care
facility; received recent intravenous antibiotic therapy, che-
motherapy, or wound care in the past 30 days; or attended a
hospital or hemodialysis clinic. Each investigator obtained
approval from an independent ethics committee or institu-
tional review board at his or her institution.
End Points and Covariates
The primary end point examined was hospital mortality. We
also examined other important covariates to include demo-
graphic characteristics, MDR status of the P. aeruginosa isolate,
and comorbidities (acute coronary syndrome, valvular heart
disease, hypertension, venous thromboembolism, chronic
obstructive pulmonary disease, asthma, other chronic
respiratory diseases, and diabetes mellitus). Patients were also
classiﬁed according to whether they received IIAT.
Deﬁnitions
To be classiﬁed as MDR, the P. aeruginosa isolate had to be
nonsusceptible to at least 1 agent in at least 3 of the following
antimicrobial categories: aminoglycosides, antipseudomonal
carbapenems, antipseudomonal cephalosporins, anti-
pseudomonal ﬂuoroquinolones, antipseudomonal penicillins
plus β-lactamase inhibitors, monobactams, phosphonic acids,
and polymixins.16 Antimicrobial treatment was deemed to
represent IIAT if the initially prescribed antibiotic regimen was
not active against the identiﬁed isolate on the basis of in vitro
susceptibility testing or was administered more than 24 hours
following respiratory specimen collection.17 Microbiology
laboratories determined antimicrobial susceptibility of the
isolates using disk diffusion or automated testing methods
according to established guidelines and breakpoints.18,19
Statistical Analyses
Continuous variables were reported as means with standard
deviations. Differences between mean values were tested via the
t test. Categorical data were summarized as proportions, and
the χ2 test or Fisher exact test for small samples was used to
examine differences between groups. We developed several
multiple logistic regression models to identify clinical risk fac-
tors associated with hospital mortality and IIAT. Risk factors
that were signiﬁcant at P≤ .20 in the univariate analyses, as well
as all biologically plausible factors even if they did not reach this
level of signiﬁcance, were included in the corresponding mul-
tivariable analyses. All variables entered into the models were
examined to assess for collinearity, and interaction terms were
tested. The most parsimonious models for the predictors of
hospital mortality and IIAT respectively were computed and
their ﬁt was tested with the area under the receiver operating
curve and the Hosmer-Lemeshow goodness-of-ﬁt test. All tests
were 2-tailed, and a P value< .05 was deemed a priori to
represent statistical signiﬁcance. On the basis of our prior
experience and available publications, we estimated that the
hospital mortality for COP would be approximately 20% and
the hospital mortality for HAP and VAPwould be between 35%
and 40%. Using a 2-sided estimate with a P value of .05 and
80% power required at least 138 patients per pneumonia type to
yield statistically meaningful estimates. Thus our goal prior to
performing the study was to have at least 150 patients per
pneumonia type during study recruitment and data collection
to ensure that our mortality analysis would be valid. All analyses
were performed with SPSS software, version 19.0 (IBM).
results
Seven hundred forty-two patients with Pa-NP met the inclu-
sion criteria and were enrolled in the study. There were 258
patients (34.8%) from the United States, 141 (19.0%) from
France, 120 (16.2%) from Germany, 115 (15.5%) from Spain,
and 108 (14.6%) from Italy. A diagnosis of pneumonia was
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made most commonly via bronchoalveolar lavage (35%),
tracheobronchial aspirate (28%), mini-bronchoalveolar
(18%), and sputum samples (15%). VAP was most common
(339 [45.7%]) followed by COP (241 [32.5%]) and HAP
(162 [21.8%]). Signiﬁcant differences in subject location prior
to hospital admission, underlying comorbidities, and vital
signs were observed by pneumonia classiﬁcation (Table 1).
Patients with VAP had the lowest Charlson comorbidity scores
and prevalence of secondary bacteremia, but VAP was asso-
ciated with the greatest use of vasopressors following
pneumonia onset. The antibiotic susceptibility of the P. aeru-
ginosa isolates was comparable for COP, HAP, and VAP
(Table 2). Similarly, the prevalence of MDR isolates and the
rate of IIAT were equivalent for all 3 pneumonia categories.
Overall hospital mortality was 35.8% (n= 266) and ranged
across centers from 12% to 60%. Hospital mortality was
greater for VAP (41.9%) and HAP (40.1%) compared with
COP (24.5%) (P< .001). This was conﬁrmed in a Kaplan-
Meier analysis (Figure 1). Hospital length of stay, uncensored
for survival, was signiﬁcantly longer for VAP compared with
HAP (Table 3). However, total durations of mechanical ven-
tilation and intensive care progressively increased going from
COP to HAP and VAP. Hospital readmission was similar
across pneumonia types. Among the HAP patients, 97 (59.9%)
developed HAP while in the intensive care unit (ICU) setting.
Hospital mortality was higher for HAP within the ICU com-
pared with HAP occurring outside of the ICU (45.4% vs
32.3%; P= .097). However, median (interquartile range)
hospital length of stay was similar for HAP within the ICU and
HAP occurring outside of the ICU (28 days [11.5–45.0 days] vs
23.0 days [12.0-37.0 days]; P= .414).
Table 4 shows the results of the logistic regression model
derivations examining the variables associated with hospital
mortality for each pneumonia category. Among subjects with
table 1. Baseline Characteristics
Characteristic
Community-onset pneumonia
(n= 241)
Hospital-acquired pneumonia
(n= 162)
Ventilator-associated pneumonia
(n= 339)
Age, mean± SD, y 57.8± 17.7 61.2± 17.2 59.7± 15.6
Male sex 155 (64.3%) 111 (68.5%) 238 (70.2%)
Location prior to admission
Community 119 (49.4%) 98 (60.5%) 172 (50.7%)c
Skilled nursing facility 29 (12.0%) 21 (13.0%) 4 (1.2%)b,c
Long-term care facility 16 (6.6%) 5 (3.1%) 6 (1.8%)b
Assisted living 4 (1.7%) 2 (1.2%) 1 (0.3%)
Inpatient rehabilitation 36 (14.9%) 6 (3.7%) 5 (1.5%)b
Other 36 (14.9%) 27 (16.7%) 147 (43.4%)b,c
Medical history
Hospitalized in the previous
6 months
173 (74.6%) 88 (57.9%)a 111 (42.5%)b,c
Sepsis 50 (21.8%) 28 (19.0%) 41 (13.5%)b
HIV 4 (1.8%) 3 (2.1%) 2 (0.7%)
Acute coronary syndrome 38 (17.3%) 20 (13.6%) 31 (10.3%)b
Valvular heart disease 34 (15.2%) 16 (10.9%) 31 (10.3%)
Hypertension 115 (49.4%) 70 (44.0%) 152 (47.1%)
Venous thromboembolic
disease
30 (13.2%) 16 (10.8%) 11 (3.6%)b,c
Asthma/COPD 77 (33.5%) 40 (26.1%) 61 (20.1%)b
Other respiratory disease 107 (48.4%) 44 (30.3%)a 49 (16.3%)b,c
Charlson comorbidity score,
mean ± SD
3.8± 2.9 3.3± 2.7 2.4 ±2.3b,c
ICU admission 117 (48.5%) 108 (66.7%)a 324 (95.6%)b,c
Mechanical ventilation 169 (70.1%) 131 (80.9%)a 339 (100%)b,c
Vasopressor administration 126 (52.3%) 95 (58.6%) 235 (69.3%)b,c
Bacteremia 88 (36.5%) 47 (29.0%) 47 (13.9%)b,c
Polymicrobial respiratory
specimen
47 (19.5%) 46 (28.4%)a 87 (25.7%)
NOTE. Data are no. (%) unless otherwise speciﬁed. COPD, chronic obstructive pulmonary disease; HIV, human immunodeﬁciency virus; ICU,
intensive care unit.
aP< .05 comparing hospital-acquired pneumonia and community-onset pneumonia.
bP< .05 comparing ventilator-associated pneumonia and community-onset pneumonia.
cP< .05 comparing ventilator-associated pneumonia and hospital-acquired pneumonia.
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COP the need for mechanical ventilation and the ICU were
independent predictors of hospital death. For subjects with
HAP only the presence of an MDR isolate was independently
associated with hospital death. Administration of IIAT, vaso-
pressor use, increasing Charlson comorbidity scores and age,
and secondary bacteremia were identiﬁed as independent
predictors of hospital mortality for VAP. MDR and bacteremia
were independent predictors of IIAT for COP (Table 5). MDR
was also an independent predictor of IIAT for HAP, whereas
increasing Charlson comorbidity scores predicted IIAT in
VAP and recent antibiotic administration was found to be
protective against IIAT.
discussion
We found that hospital mortality varied among patients with
Pa-NP according to their pneumonia classiﬁcation. Those with
VAP and HAP had signiﬁcantly greater risk of hospital death
compared with patients with COP. Moreover, the risk factors
for hospital death also varied by pneumonia classiﬁcation.
table 2. Antibiotic Resistance
Antibiotic class
% missing (of
total 742)
Community-onset
pneumonia (n= 241)
Hospital-acquired
pneumonia (n= 162)
Ventilator-associated
pneumonia (n= 339)
Aminoglycosides 1.5% 63 (26.3%) 45 (28.0%) 97 (29.4%)
Antipseudomonal carbapenems 1.1% 75 (31.5%) 58 (36.3%) 137 (40.8%)b
Antipseudomonal cephalosporins 1.6% 68 (28.3%) 39 (24.4%) 91 (27.6%)
Antipseudomonal ﬂuoroquinolones 2.4% 80 (33.5%) 48 (30.2%) 104 (31.9%)
Antipseudomonal penicillins + beta-
lactamase inhibitors
2.6% 73 (30.8%) 47 (29.4%) 107 (32.8%)
Monobactams 50.7% 45 (56.3%) 43 (47.3%) 87 (44.6%)
Phosphonic acids 74.3% 21 (60.0%) 15 (34.1%)a 35 (31.3%)b
Polymyxins 49.6% 6 (6.3%) 5 (5.7%) 10 (5.2)%
Multidrug-resistant 0.3% 74 (30.7%) 50 (30.9%) 102 (30.3%)
Inappropriate initial antibiotic
therapy
1.6% 56 (23.8%) 41 (25.6%) 93 (27.8%)
NOTE. Data are no. (%) unless otherwise indicated.
aP< .005 comparing hospital-acquired pneumonia and community-onset pneumonia.
bP< .005 comparing ventilator-associated pneumonia and community-onset pneumonia.
ﬁgure 1. Kaplan-Meier curves of cumulative survival from hospital admission. Community-onset pneumonia compared with hospital-
acquired pneumonia (P< .001; log-rank test); community-onset pneumonia compared with ventilator-associated pneumonia (P< .001; log-
rank test); hospital-acquired pneumonia compared with ventilator-associated pneumonia (P= .139, log-rank test).
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Among patients with COP, severity of illness markers including
the need formechanical ventilation and intensive care predicted
death. For the HAP cohort, infection with an MDR isolate was
found to be the most important predictor of outcome. Patients
with VAP had both severity of illness markers (need for vaso-
pressors, bacteremia, 1-point increments in the Charlson
comorbidity score) and IIAT identiﬁed as risk factors for death.
Interestingly, the rates of antibiotic resistance, multidrug resis-
tance, and inappropriate therapy were similar for COP, HAP,
and VAP, suggesting that a similar pathogen phenotype was
responsible for infection regardless of pneumonia classiﬁcation.
We also found that MDR status was an important risk factor for
IIAT among patients with COP and HAP.
Kollef et al2 previously examined a large US pneumonia
database and showed that mortality rates associated with
healthcare-associated pneumonia (HCAP) and HAP were both
signiﬁcantly higher than that for community-acquired
pneumonia and lower than that for VAP. Similarly, hospital
length of stay and hospitalization charges varied signiﬁcantly
with pneumonia category in order of ascending values for
community-acquired pneumonia, HCAP, HAP, and VAP.
These ﬁndings were conﬁrmed in a subsequent single-center
study from the United States.20 However, several authors have
criticized the use of the term HCAP, suggesting that it could
result in the needless administration of broad-spectrum
antibiotics to individuals with COP not infected with
antibiotic-resistant pathogens.21,22 An alternative approach for
classifying patients with COP is to identify the number of risk
factors for MDR infection they have in order to better direct
the use of broad-spectrum antibiotics.23 Our study found that
table 3. Outcomes
Outcome Community-onset
pneumonia (n= 241)
Hospital-acquired
pneumonia (n= 162)
Ventilator-associated
pneumonia (n= 339)
Hospital mortality, no. (%) 59 (24.5%) 65 (40.1%)a 142 (41.9%)b
Hospital length of stay, days, all subjects
Mean± SD 42.4± 52.4 31.9± 30.1 40.1± 40.7c
Median (interquartile range) 25 (13.3-53.0) 24.5 (12.0-41.0) 27.5 (14.8-53.3)
ICU duration, days
Mean± SD 13.6± 17.9 19.9± 19.0a 29.6± 25.7b,c
Median (interquartile range) 7.8 (3.8–17.7) 13.1 (6.9–24.7) 21.2 (13.9–35.5)
Duration of mechanical ventilation, days
Mean± SD 12.3± 14.6 23.2± 34.3a 27.1± 24.2b,c
Median (interquartile range) 8.7 (3.5–15.2) 11.1 (4.8–27.2) 20.9 (11.7–34.2)
30-day hospital readmission among hospital survivors, no. (%) 39/182 (21.4%) 27/97 (28.4%) 52/197 (26.4%)
NOTE. ICU, intensive care unit.
aP< .005 comparing hospital-acquired pneumonia and community-onset pneumonia.
bP< .005 comparing ventilator-associated pneumonia and community-onset pneumonia.
cP< .05 comparing ventilator-associated pneumonia and hospital-acquired pneumonia.
table 4. Independent Predictors of Mortality
Community-onset pneumonia Hospital-acquired pneumonia Ventilator-associated pneumonia
Variable AOR 95% CI P value AOR 95% CI P value AOR 95% CI P value
Inappropriate initial antibiotics 1.86 1.40–2.45 .026
Vasopressor administration 2.04 1.54–2.70 .011
Charlson comorbidity score
(increasing increments of 1)
1.14 1.08–1.20 .018
Mechanical ventilation 3.27 1.85–5.76 .037
Multidrug-resistant isolate 5.50 3.56–8.51 <.001
Age (increasing increments of 1) 1.02 1.01–1.03 .008
Bacteremia 3.72 2.49–5.55 .001
ICU admission 2.88 1.78–4.68 .029
NOTE. Factors excluded from the model for collinearity: aminoglycoside resistance, carbapenem resistance, cephalosporin resistance,
ﬂuoroquinolone resistance, penicillin-beta-lactamase inhibitor resistance (collinear with multidrug-resistant isolate). Variables included but not
retained in the model at the P< .05 in addition to those shown: corticosteroids for the ventilator-associated pneumonia analysis. Hosmer-
Lemeshow/ area under the receiver operating curve: community-onset pneumonia, 0.452/0.642; hospital-acquired pneumonia, 0.866/0.679;
ventilator-associated pneumonia, 0.698/0.620. AOR, adjusted odds ratio; ICU, intensive care unit.
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almost one-third of Pa-NP had onset in the community setting
and that the rates of MDR and IIAT were similar for COP
compared with HAP and VAP, being approximately one-third
and one-quarter respectively. Moreover, patients with COP
had the highest rates of previous hospitalization, placing them
at greater risk for infection with healthcare-associated
pathogens. This highlights the importance of correctly
identifying patients at risk for Pa-NP, regardless of the location
and conditions of their pneumonia, in order to provide
optimal medical treatment for potentially antibiotic-resistant
isolates.
Our study is unique in providing the largest cohort to date
of Pa-NP in order to assess the impact of pneumonia classiﬁ-
cation on outcomes. By focusing on a single pathogen we have
a more homogeneous population in order to minimize
pathogen-related confounders. Nevertheless, our ﬁndings are
consistent with those from studies examining NP attributed to
heterogeneous pathogens. Quartin et al24 performed a post hoc
analysis of a randomized antibiotic treatment trial in
1,184 patients. Compared with patients with HAP or VAP,
patients with COP were older, had slightly higher severity
scores, and were more likely to have comorbidities. P. aerugi-
nosa was the most common gram-negative organism isolated
in all pneumonia classes (COP,11.1%; HAP, 7.4%; VAP,
9.4%). Piskin et al25 examined 348 patients with HAP or VAP
and found that risk factors for IIAT varied by their pneumonia
type. Multiple logistic regression analysis revealed that the risk
factors for inappropriate initial therapy in HAP were late-onset
infection and greater APACHE II scores whereas in VAP
antibiotic usage in the previous 3 months and admission to a
surgical unit were found to be independent risk factors for
IIAT. Taken together with our data, these studies highlight the
difﬁculty in identifying consistent clinical markers for out-
come in NP across pneumonia categories.
A large volume of research has emphasized the importance of
early appropriate antimicrobial therapy for serious infections in
order to minimize the risk of death.26–30 It has also been shown
that escalation of treatment from IIAT to an appropriate anti-
biotic regimen in response to culture results fails to mitigate this
increase in the risk of death.31,32 Our ﬁndings generally conﬁrm
these relationships. IIAT was found to be a predictor of hospital
death in VAP where patients with VAP had the greatest severity
of illness and prevalence of septic shock. The potential practical
implications of these ﬁndings are illustrated by a recent large
epidemiologic study from the United States that identiﬁed
205,526 patients with P. aeruginosa infections (187,343
pneumonia; 18,183 bloodstream infection) and 95,566 patients
with Enterobacteriaceae infections (58,810 pneumonia; 36,756
bloodstream infection).33 The prevalence of MDR P. aeruginosa
was approximately 15-fold higher than carbapenem-resistant
Enterobacteriaceae and there was a net rise in MDR
P. aeruginosa as a proportion of all P. aeruginosa infections from
2000 to 2009. A recent meta-analysis also demonstrated that
MDR status was an important determinant of mortality due to
nosocomial infections attributed to gram-negative bacteria,
where P. aeruginosa and Acinetobacter species were the most
common isolates.34 It is also interesting that the observed
mortality for COP was lower than that observed more than 10
years ago despite the high rate of bacteremia, suggesting that
these may have been less virulent strains of gram-negative
bacteria.35
The high rates of MDR and IIAT in Pa-NP for all pneu-
monia types mandate that clinicians have therapeutic strategies
in place to optimize therapy. Scoring systems to identify
patients with MDR infections, including MDR P. aeruginosa,
are available but limited in their overall ability to predict MDR
infection.23,36,37 A number of novel methods aimed at
improving the early identiﬁcation of pathogens and related
antibiotic susceptibilities are also entering the diagnostic arena.
Such technological advances offer a strategy that could
potentially maximize the administration of appropriate
antibiotic therapy while minimizing unnecessary antibiotic
exposure. One such approach employs advanced automated
microscopy techniques that allow the identiﬁcation of bacterial
species, the determination of the presence of antibiotic resis-
tance genes, and bacterial killing by speciﬁc antibiotics within
4 to 6 hours using direct specimen inoculation.38
Our study has a number of limitations. First, it was limited to
an evaluation of Pa-NP and the ﬁndings may not be applicable
to NP attributed to other pathogens. Second, the criteria for
establishing a diagnosis of Pa-NP varied across centers. There-
fore, our study cohort could have included patients without true
pneumonia. Third, by analyzing each category of pneumonia
separately we have limited our ability to identify all important
table 5. Independent Risk Factors of Inappropriate Initial Antibiotic Therapy
Community-onset pneumonia Hospital-acquired pneumonia Ventilator-associated pneumonia
Variable AOR 95% CI P value AOR 95% CI P value AOR 95% CI P value
Prior antibiotic admission 0.54 0.39–0.73 .043
Charlson comorbidity score
(increasing increments of 1)
1.17 1.11–1.23 .003
Multidrug-resistant isolate 11.15 7.11–17.48 < .001 3.66 2.28–5.89 .006
Bacteremia 3.2 1.92–5.33 .022
NOTE. Hosmer-Lemeshow/ area under the receiver operating curve: community-onset pneumonia, 0.453/0.691; hospital-acquired pneumonia,
0.721/0.641; ventilator-associated pneumonia, 0.731/0.609. AOR, adjusted odds ratio.
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risk factors for hospital mortality and IIAT. Larger cohorts
might show more-similar risk factors for these outcomes.
Fourth, our deﬁnition of COP included patients who previously
would have been classiﬁed as HCAP. However, given the con-
troversies surrounding the HCAP deﬁnition we chose to simply
deﬁne patients acquiring Pa-NP outside of the hospital as
community-onset. In addition, we did not assess the type of
prior antibiotics administered nor did we assess how clinicians
made decisions regarding the selection of empirical antibiotic
therapy in this cohort. This may have been important, especially
if the administration of prior antibiotics gave rise to broader
subsequent empirical therapy resulting in less IIAT as suggested
by the VAP analysis. Finally, we did not require the study sites to
provide information on the overall number of patients screened
or the number of patients with possible Pseudomonas pneu-
monia that were excluded for not meeting the entry criteria. We
recognize that this is a potential bias of our study, potentially
selecting out a cohort of patients with Pseudomonas pneumonia
that may not be representative of all patients with this infection.
In summary, our study found that for Pa-NP, pneumonia
classiﬁcation identiﬁed patients with different risks for hospital
mortality. Risk factors for hospital mortality also differed by
pneumonia classiﬁcation and multidrug resistance appeared to
be a common risk factor for IIAT. These ﬁndings suggest that
pneumonia classiﬁcation for P. aeruginosa identiﬁes patients
with different mortality risks and speciﬁc risk factors for
outcome and IIAT.
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APPENDIX 1 . Number of Subjects Enrolled at each Center
and Corresponding Hospital Mortality Rate (%)
Groupe Hospitalier Pitie-Saltpetriere, France, n= 100 (38%)
Hopital Raymond Poincare, France, n= 41 (37%)
University Hospital of Munich, Germany, n= 41 (12%)
Medizinische Hochschule Hannover, Germany, n= 79 (57%)
Polclinica Universitario A Gemelli, Italy, n= 83 (46%)
Azienda Ospedaliera Universitaria Pisana, Italy, n= 25 (48%)
Hospital Universitari Mutua De Terrassa, Spain, n= 27 (26%)
Hospital Vall D’Hebron, Spain, n= 62 (60%)
Hospital Clinic De Barcelona, Spain, n= 26 (42%)
Barnes-Jewish Hospital, United States, n= 100 (15%)
Northwestern Memorial Hospital, United States, n= 78 (19%)
Mayo Clinic, United States, n = 80 (36%)
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